Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Skip the scope? A rapid fecal calprotectin (FC) test may help doctors rule out serious colon problems in patients with chronic diarrhea — no colonoscopy required. A large prospective study across 15 centers in China found the 15-minute stool test accurately distinguished normal colon findings from inflammation and IBD, with a strong negative predictive value. It could be a meaningful step toward reducing invasive procedures.
A rapid fecal calprotectin (FC) assay — delivering results in just 15 minutes — showed strong diagnostic accuracy in distinguishing normal colon findings from significant abnormalities in patients with chronic diarrhea, according to a new prospective study published in the Journal of Gastroenterology and Hepatology. Conducted across 15 clinical centers in China, the study enrolled 556 patients with chronic diarrhea and 152 healthy controls, evaluating FC levels against colonoscopy results.
The test performed especially well at ruling out inflammatory bowel disease (IBD), with a negative predictive value (NPV) of 97.3% at a cutoff of 157.0 μg/g — meaning a negative result can give both clinicians and patients strong confidence that IBD is unlikely, potentially avoiding the need for colonoscopy altogether. However, the test showed limited accuracy for detecting high-risk adenomas.
By the Numbers:
Why it matters: Colonoscopies are invasive, costly, and resource-intensive. A reliable, rapid, noninvasive rule-out tool like the FC assay could meaningfully reduce unnecessary procedures, ease patient burden, and help triage who truly needs further workup.